Quarterly ResultAug 5, 2026, 04:09 PM
OraSure Q2 Net Income $6.2M; EPS $0.09; Revenue $30.6M
AI Summary
OraSure Technologies reported a return to profitability in Q2 2026, with GAAP net income of $6.2 million and diluted EPS of $0.09, a significant improvement from a net loss in the prior year. Total net revenues reached $30.6 million, showing a 9.7% sequential increase and exceeding guidance, despite a slight year-over-year decline. The company also announced key innovation milestones, including FDA clearance for its Colli-Pee™•Dx at-home urine collection device and FDA Emergency Use Authorization for its OraQuick™ Ebola 2.0 Rapid Antigen Test. OraSure provided Q3 2026 revenue guidance of $29.5 million to $32.5 million.
Key Highlights
- Q2 2026 total net revenues were $30.6 million, a 2% decrease year-over-year but up 9.7% sequentially.
- GAAP net income for Q2 2026 was $6.2 million, compared to a net loss of $19.7 million in Q2 2025.
- Diluted EPS was $0.09 in Q2 2026, a significant improvement from $(0.26) in Q2 2025.
- GAAP gross margin improved to 43.5% in Q2 2026 from 42.1% in Q2 2025.
- FDA clearance received for Colli-Pee™•Dx at-home urine collection device in June 2026.
- FDA Emergency Use Authorization granted for OraQuick™ Ebola 2.0 Rapid Antigen Test in July 2026.
- Repurchased $2 million of common stock in Q2 2026, totaling $22 million (7.7 million shares) under the $40 million authorization.
- Q3 2026 revenue guidance is set between $29.5 million and $32.5 million.
Price Impact
More from OSUR